88
Participants
Start Date
January 12, 2021
Primary Completion Date
December 31, 2025
Study Completion Date
June 30, 2026
PrEP acronym (pre-exposure prophylaxis)
A daily tablet containing 245 mg of tenofovir disoproxil fumarate and 200 mg emtricitabine (Truvada; Gilead Sciences) for up to 30 days.
Initial Web Survey
Web-based assessment questions regarding alcohol and other substance use and sexual health behaviors
Interactive Voice Response (IVR) monitoring
Daily telephone-based assessment on alcohol and other substance use, sexual health behavior and PrEP taking
Educational material on alcohol and sexual health behavior
Educational material to provide information, resources and techniques to enhance awareness regarding alcohol and other substance use, along with sexual health behavior.
Interactive Voice Response (IVR) assessment with personalized information
Daily telephone-based assessment on alcohol and other substance use, sexual health behavior and PrEP taking with personalized and information based on daily IVR responses
Personalized information based on web-based survey responses & standardized information
Personalized and information on alcohol use and sexual health behavior based on responses to the web-based survey along with standardized information.
RECRUITING
University of Florida, Gainesville
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
University of Florida
OTHER